ライフサイエンスコーパス: type II

1 ed through hematite reduction by dithionite (type II).

2 and another with a discontinuous transition (Type II).

3 of tobacco use, asthma, or diabetes mellitus type II.

4 tions in bone morphogenetic protein receptor type II.

5 t in engineered cartilage against interferon type II.

6 +/- 2 M(-2) s(-1); whereas within confining type-(ii) 12-MR pockets, there is a ~5-fold enhancement

7 s; Type-I (21 Malpha, 4 Mbeta, 4 Mgamma) and Type-II (32 MIKCc, 2 MIKC*) through phylogenetic analysi

8 s that control accurate spacer uptake in the type II-A CRISPR locus of Streptococcus thermophilus.

9 Among type II-A CRISPR systems, three distinct groups (G1, G2,

10 nsion of the targetable sequence space for a type II-A CRISPR-associated enzyme through identificatio

11 ce interactions within the seemingly similar type II-A integration complexes and provide mechanistic

12 Type II-A SpCas9 from Streptococcus pyogenes was the fir

13 Type II-A SpCas9 protein from Streptococcus pyogenes is

14 ccus and Staphylococcus genomes, can inhibit type II-A SpyCas9 or SauCas9, and are thus named acrIIA1

15 In type II-A systems, Cas1 and Cas2 proteins insert prespac

16 riptions of other solute binding proteins of type II ABC transporters.

17 o elucidate the X-ray crystal structure of a type II ACP-AT complex.

18 mixed meso/microporous monoliths demonstrate Type II adsorption isotherms to achieve benchmark volume

19 and holes in the intralayer excitons with a type II alignment, but it will funnel excitons into one

20 ng unraveled and is based on initiation of a type II allergic response to specific food antigens, lea

21 d (RA) and supports the synthesis of RA from type II alveolar ECs to suppress excessive activation of

22 oire of murine lower airway tissues, primary type II alveolar epithelial cells (AECIIs), and the mous

23 This process occurs when type II alveolar pneumocytes (AT2 cells) proliferate and

24 he misfolding of proteins including diabetes type II, Alzheimer's, and Parkinson's disease.

25 ding to the genotypes of the isolates for 13 type II and 21 non-type II samples.

26 Predicted responders (type II and III and Pcrit < 1 cmH(2) O) exhibited a grea

27 genic latent viral antigens expressed in EBV type II and III latency tumors, such as posttransplant l

28 Type II and III taste bud cells (TBCs) detect molecules

29 ade according to the genotype of the strain (type II and non-type II genotypes).

30 re capable of signaling through a complex of type II and type I receptors.

31 e architecture of the T4aP secretin from the type II and type III secretion system secretins.

32 ty is essential for reciprocal regulation of types II and III iodothyronine deiodinases (Dio2 and Dio

33 fluorescence microscopy of MOCS1AB variants (types II and III) revealed that they were targeted to mi

34 Comparisons between extreme skin types II and VI showed melanin inhibition factors of app

35 pond with the presence of V-type polymorphs (Type II) and increased in relative crystallinity showed

36 vels of TOLLIP include macrophages, alveolar type II, and basal cells.

37 atory subunit type I, PKA regulatory subunit type II, and Ca(2+)/calmodulin-dependent protein kinase

38 at most neonatally-derived hair cells become Type II, and many Type I hair cells (formed before P2) d

39 me, membranoproliferative glomerulonephritis type II, and paroxysmal nocturnal hemoglobinuria.

40 the pathophysiology of cardiorenal syndrome type II, and with acute volume overload decompensation o

41 AT(1)R, in particular, angiotensin receptor type II (AT(2)R), resulting in biological and physiologi

42 MHC-II on alveolar type-II (AT-II) cells is associated with immune toleranc

43 key regulator of ER homeostasis, in alveolar type II (AT2) cells, progenitors of distal lung epitheli

44 from single adult human alveolar epithelial type II (AT2) or KRT5(+) basal cells.

45 J) repair pathway and DNA damage in alveolar type II (ATII) cells and emphysema development.

46 interface (ALI) model of alveolar epithelial type II (ATII)-like cell differentiation that allows us

47 cal pause or asystole; (2) high-grade Mobitz type II atrioventricular block or complete heart block;

48 showed mild myopathic changes with selective type II atrophy.

49 In this work we show that the Type-II band-alignment between tungsten diselenide and c

50 del, comprising immortalised bovine alveolar type II (BATII) epithelial cells and bovine pulmonary ar

51 that these highly dynamic peptides harbor a type II beta-turn located in their central part.

52 Loss of function mutations in the type II BMP receptor BMPR2 are the leading cause of pulm

53 stinct recycling pathways for the type I and type II BMP receptors and highlights the importance of t

54 The more compact Type II-C Cas9 orthologs can help to overcome the size l

55 9 found in Listeria (similar to SauCas9) and Type II-C Cas9s, likely due to Cas9 HNH domain conservat

56 Here, we characterize CcCas9, a Type II-C CRISPR nuclease from Clostridium cellulolyticu

57 icus CRISPR-Cas9 (AceCas9) is a thermophilic Type II-C enzyme that has potential genome editing appli

58 Yet, only a few Type II-C nucleases were fully characterized to date.

59 e show how tissue-specific expression of the type II cadherin, Cadherin2, patterns actomyosin contrac

60 ere we report that solubilization of a GPCR, type II cannabinoid receptor CB(2), in a Facade detergen

61 A second novel sub-type, i.e., Type II cells (64% of total) generated rhythmic, global

62 he extent of injury, both remaining alveolar type II cells (AEC2s) and distal airway stem/progenitors

63 Type II cells (aka receptor cells) possess a large round

64 reduced proliferative potential of alveolar type II cells and club cells, increased cellular senesce

65 Thus, the spatiotemporal characteristics of Type II cells and their dependence upon Cav(L) and ANO1

66 ncy that were synchronised with neighbouring Type II cells and were abolished following blockade of e

67 opment is restricted to a subset of alveolar type II cells expressing Hnf1b.

68 n cRaf-induced tumors in alveolar epithelial type II cells restricted tumor formation, whereas activa

69 udes PDGF secretion from alveolar type I and type II cells, cell shape changes of type I cells and mi

70 pholipids and proteins, secreted by alveolar type II cells.

71 epithelial cells and morphologically mature type II cells.

72 ctant protein C-positive alveolar epithelial type-II cells.

73 erminal substrate binding domain, similar to type II cellular J proteins.

74 lkit for genetic manipulations of type I and type II cochlear afferent fibers.

75 Coculture groups demonstrated higher type II collagen expression compared to the MSC monocult

76 Abundant type II collagen fibers developed on day 21; while Sox9,

77 [-1A]TIMP3 driven by a chondrocyte-specific type II collagen promoter.

78 The levels of Sox9, type II collagen, aggrecan, type I collagen, Runx2, type

79 agen fibers developed on day 21; while Sox9, type II collagen, and aggrecan expression increased over

80 ease in expression of chondrogenic markers - type II collagen, sox9, aggrecan, and hedgehog (Hh) sign

81 Deletion of IFT80 in type II collagen-positive cells resulted in cilia loss i

82 stablish anisotropic carrier separation near type II core-shell interfaces and extended long-waveleng

83 he carrier separation, such as the design of type-II core-shell structure and versatile surface modif

84 Bacterial Cas9 nucleases from type II CRISPR-Cas antiviral defence systems have been r

85 Type II CRISPR-Cas systems defend prokaryotes from bacte

86 Type II CRISPR-Cas systems provide immunity against phag

87 Type II CRISPR-Cas9 RNA-guided nucleases are widely used

88 Citrullinemia type II (CTLN-II) is an inherited disorder caused by ger

89 Synthesis of bridged scaffolds via Type II cyclization constitutes substantial challenges d

90 I)-catalyzed enantioselective intramolecular Type II cyclization of alkynes via C-C activation of cyc

91 Catalytic enantioselective Type II-cyclization methods are even rarer.

92 ECM)-associated matrisome network, including type II cystatin gene cluster, mucin 5, and cathepsin lo

93 uding an unusual class that emerges from the type-II degeneracies residing in the complex space of k.

94 Type II diabetes (T2D) may worsen the course of hepatiti

95 id fibrils in more than 90% of patients with type II diabetes (T2D).

96 n occur in tandem in cardiovascular disease, type II diabetes and ageing.

97 HCC, including metabolic syndrome, obesity, type II diabetes and non-alcoholic fatty liver disease (

98 hIAPP), is the major factor for categorizing Type II diabetes as an amyloid disease.

99 s importance in metabolic disease, including Type II Diabetes Mellitus (T2DM) and obesity.

100 of 3501-8000 birr [AOR = 4.54;(1.31-15.7)], type II diabetes mellitus [AOR = 3.9;(1.6-9.6)], duratio

101 Older patients with obesity/type II diabetes mellitus frequently present with advanc

102 in the prevalence of obesity and associated type II diabetes mellitus is a major health concern, par

103 rtension, hyperlipidemia, cigarette smoking, type II diabetes mellitus, and end-stage renal disease r

104 rtension, hyperlipidemia, cigarette smoking, type II diabetes mellitus, and end-stage renal disease r

105 nsion and in all cases a rise in obesity and type II diabetes mellitus.

106 traits including diseases (e.g., type I and type II diabetes), disease risk factors (e.g., increased

107 onstrated hydrogelation of the amyloidogenic type II diabetes-associated islet amyloid polypeptide (I

108 and promote inflammation that contributes to type II diabetes.

109 arrier as well as an in vivo murine model of type II diabetes.

110 ture of many age-related diseases, including Type II diabetes.

111 risk among African Americans and people with type II diabetes.

112 odel that has both phenotypes of obesity and type II diabetes.

113 and reduce obesity, insulin resistance, and type II diabetes.

114 GLP-1 receptor agonist recently approved for Type-II diabetes (T2D) treatment with superior hypoglyce

115 arkinson's disease, multifactor disorder and Type-II diabetes.

116 Ni d orbital states shifts the energy of the Type-II Dirac point close to the Fermi level.

117 Here we show that NiTe(2) hosts both bulk Type-II Dirac points and topological surface states.

118 Here, we report the synthesis of the type-II Dirac semimetal Ir(2)In(8)S, an air-stable compo

119 We reveal the FXII fibronectin type II domain (FnII) binds gC1qR in a Zn2+-dependent fa

120 ving a double bromine addition followed by a type II dyotropic reaction with concomitant re-aromatiza

121 COF containing a periodic array of oriented, type II electronic heterojunctions is reported.

122 erum, bronchoalveolar lavage fluid, alveolar type II epithelial cells, and alveolar myeloid cells of

123 Type I and Type II error rates were examined across a range of prio

124 I error' cases, and false-negative (FN) or 'type II error' cases were ascertained by Bayes' theorem.

125 luded GWASs, potentially leading to possible type II error.

126 We note that possible type II errors may be present due to the small sample si

127 ection, which results in increased Type I or Type II errors.

128 defined by prior precedent, thereby reducing Type II errors.

129 D, and its cognate ACP, AcpP, to interrogate type II FAS ACP-AT interactions.

130 bidopsis thaliana) mitochondrially localized Type II FAS.

131 The fatty acid synthase type II (FAS-II) multienzyme system builds the main chai

132 The approach is broadly applicable to type II fatty acid synthase systems found in plants and

133 nserved cofactor protein that is required by Type II fatty acid synthases (FASs).

134 ace-bound IgE but independent of FcgammaRII, type II Fc receptors, C-type lectin receptors, and siali

135 al immune diversification through type I and type II FcgammaR-mediated cellular functions.

136 hanges of IgG1 that enable interactions with type II FcgammaRs; these receptors mediate cellular func

137 EGFP lines described previously for labeling type II fibers, the mouse lines reported here comprise a

138 in muscle cross-sectional area, strength and type II fibre-type transitions.

139 for masseter (DSC), indicates that myosin in type II fibres is more sensitive to thermal denaturation

140 rtinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus

141 within a protruding loop in the fibronectin type-II (FNII) domain of uPARAP that are also critical f

142 thway genes are emerging as a major cause of type II focal cortical dysplasia (FCD), hemimegalencepha

143 All copepods demonstrated higher magnitude type II functional responses towards the invasive prey o

144 Both displayed saturating Type-II functional responses, but juvenile functional re

145 gs of a chromosomal inversion within the MHC type II gene region in ruminants, and suggests that whit

146 e to a chromosomal inversion that splits MHC type II genes into two subregions (IIa, IIb).

147 the genotype of the strain (type II and non-type II genotypes).

148 in regard to the efficacy of Rep 529 for non-type II genotypes.

149 ts a developmental model in which Type-I and Type-II hair cells develop in parallel rather than from

150 nct, persistent T. gondii strains (Prugniaud/type II/haplogroup 2 and CEP/type III/haplogroup 3) and

151 r "straddling-gap" type-I or "staggered-gap" type-II heterojunctions.

152 e for hypertension, diet-controlled diabetes type II, high cholesterol, and a past history of numerou

153 Here, we report that the type II HpcH aldolases efficiently catalyze fluoropyruva

154 Type II IFN (IFN-gamma) is a proinflammatory T lymphocyt

155 n essential negative regulator of type I and type II IFN signaling.

156 The production of IFN-gamma, a type II IFN, was decreased in patients in response to st

157 erized by increased expression of type I and type II IFN-stimulated genes and proapoptotic genes.

158 Neither type I nor type II IFNs are required to generate CD122+Macs, howeve

159 ation, we examined the effects of type I and type II IFNs on S. aureus adherence and invasion.

160 udy the transcriptomic effects of type I and type II IFNs on SLE versus control keratinocytes.

161 ent just over 50% of the population, whereas Types II, III, and IV (basal cells) represent 19, 15, an

162 gene-therapy to treat EBV-associated latency type II/III malignancies.

163 ly the first, MOCS1A, is translated, whereas type II/III splicing produces MOCS1AB proteins.

164 rus (EBV)-associated malignancies of latency type II/III that express EBV-antigens (LMP1/2).

165 ed as a marker of tuft cells, which regulate type II immunity in the gut.

166 ype-(i) vs -56 J mol(-1) K(-1) for confining type-(ii)), indicating that confinement leads to more fa

167 on of a new class of bacterial topoisomerase type II inhibitors known as "novel bacterial topoisomera

168 inhibitors, we found that they both bind as type II inhibitors with IRAK4 in a "DFG-out" conformatio

169 n, which is essentially required for binding type II inhibitors.

170 P site, screening identified ATP-competitive type-II inhibitors for ROR1.

171 ibitors; however, so far no highly selective type-II inhibitors have been reported.

172 ressor, inositol-polyphosphate 4-phosphatase type II (INPP4B), can partially compensate for the loss

173 eprograms HSCs in the bone marrow (BM) via a type II interferon (IFN-II) or interleukin-1 (IL1) respo

174 nate immune response by elevating type I and type II interferon levels.

175 virus infection impaired AM crawling via the type II interferon signaling pathway, and this greatly i

176 Upregulation of PD-L1 on DC is mediated by type II interferon.

177 sly identified as negative regulators of the type-II interferon response (for example, Ptpn2, Socs1 a

178 In contrast, type II is well-tolerated in normal monkeys and shows bo

179 icipants (30-45 years) with Fitzpatrick skin type II-IV were randomly assigned (1:1:1) to 1000 mg of

180 the inhibition of ternary CDK8 complexes by type II kinase inhibitors.

181 osed mechanism of hydrolysis of L-Asn by the type II L-asparaginase from E. coli (EcAII), but that wo

182 The hPSC-LOs (particularly alveolar type-II-like cells) are permissive to SARS-CoV-2 infecti

183 The lower-inner (type II) location was the most usual, followed by the lo

184 ognition mechanism appears to occur with the Type II M.HinfI DNA methyltransferase and an ortholog of

185 sted: A type I active-site binding mAb and a type II mAb binding to an exosite on APC (required for a

186 Our data show that the type II mAb can specifically inhibit APC's anticoagulant

187 yield is controlled by variant alleles of a type II MADS-box gene, SHELL, that impact the presence a

188 sneak or satellite spawning tactic, whereas type II males only cuckold.

189 males during spawning compared to cuckolding type II males.

190 ive photodynamic therapy via both type I and type II mechanisms.

191 MnO(3) (R = rare-earth cation) compounds are type-II multiferroics induced by inversion-symmetry-brea

192 r (fibre type I) and cutaneous trunci (fibre type II) muscles by Differential Scanning Calorimetry (D

193 tion (type I mutation) and a 5-bp insertion (type II mutation) are the most frequent genetic lesions.

194 We found that TtDdl is a type II MVC-activated enzyme, retaining activity in the

195 ryotic cells divide by furrowing but have no type-II myosin, making it unlikely that an actomyosin ri

196 contraction of a ring containing F-actin and type-II myosin.

197 pertension (n=75), and 12% diabetes mellitus type II (n=28).

198 Type II NADH:quinone oxidoreductase (NDH-2) plays a cruc

199 lysis corroborated that WSUCF1 biofilms uses type-II NADH dehydrogenase and demethylmenaquinone methy

200 Type II NADs are enriched in distinct gene classes, incl

201 Type II NADs tend to replicate earlier, display greater

202 ly required for altering lineage patterns in type II neuroblasts (NBs), one of the two main Drosophil

203 SG type I (Slc17a7, Calb1, Pou4f1, Cal2) and type II neurons (Prph, Plk5, Cacna1g).

204 In addition, we demonstrate that type II neurons belong to a previously neglected class o

205 The type II nuclear receptors (NRs) function as heterodimeri

206 ealed a decreased proportion of fiber type I/type II only in SOL muscles but not in the extensor digi

207 yketide synthase type I, polyketide synthase type II or non-ribosomal peptide synthase genes within t

208 ttern (OR, 3.9, P=0.0068), diabetes mellitus type II (OR, 4.1, P=0.046), and beta-blocker use (OR, 3.

209 weight [OR, 2.6, P=0.023], diabetes mellitus type II [OR, 2.9, P=0.041], certain chemotherapies [plat

210 Type II PAKs (PAK4, -5, and -6) are recruited to cell-ce

211 ch are supposed to be less virulent than the type II parasites, had a lower rate of long-term surviva

212 ays, while it reduces photochemical reaction type-II pathways resulting in promotion of hydrogen pero

213 e glaucoma with narrow or closed angles; MPS type II patients tend to have plateau iris; MPS type IV

214 del (breaking, also, the barrier towards the type-II phase) and arbitrarily define the location, anis

215 reover, CD63-mediated SG maturation requires type II phosphatidylinositol 4 kinase (PI4KII)-dependent

216 Within this work, we identified a cryptic type II PKS gene cluster (skt) from Streptomyces sp. Tu

217 esis of aromatic polyketides using bacterial type II PKSs in E. coli, providing full access to its ma

218 and TMPRSS2 co-expressing cells within lung type II pneumocytes, ileal absorptive enterocytes, and n

219 ese compounds, which are produced by a novel type II polyketide synthase (PKS).

220 talytic role for ABM superfamily proteins in type II polyketide synthase assemblages for maintaining

221 The structural diversity of type II polyketides is largely generated by tailoring en

222 the addition of excess 15-crown-5 affords a Type II porous liquid.

223 Type I blocks all APC activities, whereas type II preserves APC's cytoprotective function.

224 ein kinase (MAPK) inhibitors, which reverses Type II priming, both partially attenuated OIHP.

225 , not attenuated by inhibitors of Type I and Type II priming, remains to be elucidated.SIGNIFICANCE S

226 P treated with agents that reverse Type I or Type II priming.

227 ts in vitro and has properties of Type I and Type II priming.

228 DNA-FISH, which also detected Type I but not Type II probes enriched at the nuclear lamina.

229 Alveolar Type II progenitor cell density and self-renewal were ma

230 Epigenetic regulation by the type II protein arginine methyltransferase, PRMT5, plays

231 Deletion of GRA12 in type I RH and type II Pru T. gondii strains did not affect the parasit

232 ly caused by highly reactive singlet oxygen (Type II reaction).

233 a signaling in tenocyte function the TGFbeta type II receptor (Tgfbr2) was targeted in the Scleraxis-

234 ght to be a ligand trap for BMP9, preventing type II receptor binding and BMP9 signaling.

235 hibit reduced cell-surface levels of the BMP type II receptor DAF-4/BMPRII, along with impaired endos

236 Here, we investigated the roles of two type II receptors (ACVR2 and ACVR2B) and two type I rece

237 ere is functional redundancy between the two type II receptors as well as between the two type I rece

238 ta1 in platelets (Plt.TGFbeta-KO) or TGFbeta type II receptors in endothelial cells (End.TGFbetaRII-K

239 gative muscle regulators through the activin type II receptors with bimagrumab treatment safely incre

240 HhaI, a Type II restriction endonuclease, recognizes the symmetr

241 Type II ribosome-dependent toxins adopt a RelE-family RN

242 The most common type of vascular loop was type II (right: 69.14%; left: 58.75%).

243 Importantly, the IGFBP7-induced type II rosetting hampers phagocytosis of IRBC by host p

244 and receptors on URBC, the IGFBP7-mediated, type II rosetting requires two additional serum factors,

245 FKBP12 and FKBP12.6, and phosphorylation on type II ryanodine receptor (RyR2) arrangement and functi

246 es of the isolates for 13 type II and 21 non-type II samples.

247 The type II secretion system (T2SS) is a multi-protein compl

248 It was previously determined that the type II secretion system (T2SS) promotes the ability of

249 y showed that the enzyme is secreted via the type II secretion system and results in higher extracell

250 We further show that the type II secretion system is required for translocation a

251 ntly documented that the bacterium encodes a type II secretion system which triggers detachment-induc

252 the amounts of LcrV enclosed in OMVs by the type II secretion system, and eliminated harmful factors

253 Secretion of the enzyme requires a Type II secretion system.

254 Bacterial type II secretion systems (T2SSs) translocate virulence

255 ding transcription activator-like effectors, type II secretion systems, diversity resulting in host s

256 s both the virulence-associated type III and type II secretion systems.

257 CORIN is a transmembrane type II serine protease expressed in cardiomyocytes that

258 Type II single-span membrane proteins, such as CadC or R

259 y molecular mechanisms underlying Type I and Type II-specific effects, distinguishing between modulat

260 IC(50) values and bind to the enzyme with a type II spectral change (indicative of nitrogen-iron bon

261 taspy tachyzoites of a luciferase-expressing type II strain exhibited infection kinetics in mice simi

262 thionite oxidation product, lowered k(SA) in type II system by ~10-fold via at least two mechanisms:

263 Whether and how pre-existing spacers in type II systems affect the acquisition of new ones is un

264 Unlike type I and type II systems, type III systems do not require a proto

265 characteristic features of DinJ-YafQ family Type II TA systems in general, the toxin component is di

266 Type II tail-anchored (TA) membrane proteins are involve

267 The classic type II taste cell transcription factor POU2F3 is lineag

268 The type II TFs regulate floral organ identity and flowering

269 jor classes of PVT neurons-termed type I and type II-that differ in terms of gene expression, anatomy

270 We find that a shift from an ancestral Type-II to a modern Type-I population coincides with an

271 dispensable for the repair of topoisomerase type II (Top II) DNA adducts and associated DSBs.

272 Type II topoisomerase (TopoII) enzymes play an important

273 TOP2B encodes a type II topoisomerase, an essential gene required to all

274 When gyrase, the sole T. thermophilus type II topoisomerase, is inhibited, TtAgo allows the ba

275 ion of DNA synthesis, even in the absence of type II topoisomerase.

276 recise mapping of prokaryotic and eukaryotic type II topoisomerases cleavage sites in a variety of or

277 and SV40, the release of torsional strain by type II topoisomerases is critical for converging replis

278 Type II topoisomerases regulate DNA topology by making a

279 Inhibition of type II topoisomerases suppresses the action of other dr

280 In particular, type-II topoisomerases change both $K$ and $\Delta Lk$ b

281 YoeB-YefM, the widespread type II toxin-antitoxin (TA) module, binds to its own pr

282 Type II toxin-antitoxin pairs are regulated at the trans

283 s in its regulation as compared to classical type II toxin-antitoxin systems.

284 Type II toxin-antitoxins systems are widespread in proka

285 we report that Selenoprotein N (SEPN1) is a type II transmembrane protein that senses ER calcium flu

286 The type II transmembrane serine protease (TTSP) family enco

287 The type II transmembrane serine protease Matriptase 1 (ST14

288 The type II transmembrane serine proteases (TTSPs) are a fam

289 atriptase and hepsin belong to the family of type II transmembrane serine proteases (TTSPs).

290 Matriptase-2 (MT2) is a type-II transmembrane, trypsin-like serine protease that

291 e flip of a peptide plane from a type I to a type II' turn facilitates transformation to cross-beta s

292 n the two type I receptors and that all four type II/type I receptor combinations are utilized in viv

293 indings indicate that Asic5 is important for type II UBC activity and that loss of Asic5 contributes

294 st firing frequency was elevated in knockout type II UBCs because it was initiated from a more depola

295 nnel 5 (Asic5), which is richly expressed in type II UBCs, is sufficient to cause ataxia.

296 bsequent to this hyperpolarization in normal type II UBCs.

297 ung volunteers (n = 102) of Fitzpatrick skin types II-VI (white to black).

298 kin type groups were compared, and only skin type II was significantly steeper than the other groups.

299 nature to distinguish between the type-I and type-II Weyl semimetals.

300 that the type I ZmMC1 and ZmMC2, but not the type II ZmMC9, suppress the HR-inducing activity of the